Featured Articles

1. M&A In GLP-1 Technology: Practical Recommendations And Best Practices 11/4/2025

   With explosive demand, expanding indications, and rapid innovation, the GLP-1 revolution is reshaping dealmaking. Here's a practical guide for companies negotiating M&A in this arena.

2. How The U.S. Can Beat China In Biotech 11/3/2025

   Lumen Bioscience's Brian Finrow breaks down China's biotech playbook and explores ways the U.S. can adapt it for its own continued success.

3. Makary Talks Faster Drug Reviews, 'Continuous Trials,' DTC Ads 10/31/2025

   Part one of a two-part series on FDA Commissioner Martin Makary, M.D.'s comments at the Gailen Forum in New York City on October 30, 2025.

4. The Power Of Women Shaping The Future Of Healthcare 10/29/2025

   Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes former Melinta Therapeutics CEO Christine Ann Miller.

5. Royalties In Hybrid Licensing Agreements: Careful Drafting Is Critical 10/27/2025

   Pay close attention to contract language regarding royalties, including when and where patents expire, or pay the price, write experts at Faegre Drinker and Aurobindo Pharma USA.

6. Are Companies Bought, Not Sold? Rethinking M&A In Life Sciences 10/24/2025

   Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write Outcome Capital's Oded Ben-Joseph, Ph.D. and Peter Meyer, Ph.D.

7. The Moral Economics Of Precision Medicine 10/21/2025

   The most complex and expensive drugs to develop often target terrible diseases that affect only a small number of people and will never reach blockbuster status.

8. How The New Biotech Market Is Redefining Leadership 10/20/2025

   The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and investor relations are paramount, writes Jeff Walsh, CEO of nChroma Bio.

9. Reading The FDA Tea Leaves On Psychedelics 10/17/2025

   MAPS founder Rick Doblin accused the FDA of changing the goal posts after Lykos's MDMA Complete Response Letter was released, and offered insights for other psychedelic developers.

10. 100% Drug Tariffs Are A Dire Threat — And Patients Can't Wait 10/15/2025

    Now is the time for leaders in Washington to act to protect patients, safeguard innovation, and strengthen our economy, writes BioNJ president and CEO Debbie Hart.